The Virtual Investor “What This Means” segment featuring Outlook Therapeutics is now available here.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.